$GNPX News

Genprex Receives Notice Of Allowance From CIPO For Patent Covering Use Of Reqorsa Gene Therapy In Combination With Either PD-1 Or PD-L1 Antibodies For Treatment Of Lung Cancer

Genprex Receives Nasdaq Noncompliance Notice

Genprex Files For Mixed Shelf Of Up To $250M

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting

Genprex Q1 EPS $(0.64) Up From $(13.00) YoY

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Israel Patent Office Grants Genprex Patent Covering Use Of Reqorsa Gene Therapy In Combination With PD-1 Antibodies For Treatment Of Cancer

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

Genprex Signs Research Agreement With MD Anderson To Study Biomarkers Predicting Response To Reqorsa Gene Therapy In Lung Cancer Trials

Genprex Signs Research Agreement With MD Anderson To Study Biomarkers Predicting Response To Reqorsa Gene Therapy In Lung Cancer Trials

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex Research Collaborators Presents Preclinical Data From Studies Of Lead Drug Candidate, Reqorsa Gene Therapy For Treatment Of Lung Cancer At 2026 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex Collaborators To Present Positive Preclinical REQORSA Gene Therapy Lung Cancer Data At AACR 2026

Genprex to Participate at BIO Europe Spring 2026

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer